Melatonin Effects on the Left Ventricular Function in Neonates With Persistent Pulmonary Hypertension
NCT ID: NCT07090720
Last Updated: 2025-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2023-01-01
2025-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns
NCT05741229
High Risk Factor, Clinical Feature, and Follow up of Neonatal Arrhythmia
NCT04899596
Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies
NCT01695070
Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn
NCT04898114
Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies
NCT00725647
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Melatonin, a neurohormone produced by the pineal gland, offers an exceptional defense against reactive oxygen species (ROS). Infants are unable to synthesize melatonin during their first few weeks of life, which may exacerbate oxidative stress in hypoxic conditions. Additionally, Melatonin's antioxidative capabilities have been shown in neonatal pulmonary and respiratory disorders.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
Neonates were given Melatonin.
Melatonin
Neonates were given Melatonin.
Group II
Neonates received placebo.
Placebo
Neonates received placebo.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Melatonin
Neonates were given Melatonin.
Placebo
Neonates received placebo.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Admitted with persistent pulmonary hypertension.
Exclusion Criteria
* Infants with congenital heart diseases.
* Infants with dysrhythmia.
* Chromosomal abnormalities.
* Severe pathological jaundice.
* Metabolic or endocrinal disorders.
* Major congenital malformations.
36 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asmaa Mahmoud Abdel Hamid Elmesiry
Lecturer of Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, El-Gharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36173//12/22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.